Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
January-2015 Volume 11 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
January-2015 Volume 11 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Anti‑metastatic effect of Smilax china L. extract on MDA‑MB‑231 cells

  • Authors:
    • Kyoung Jin Nho
    • Jin Mi Chun
    • Ho Kyoung Kim
  • View Affiliations / Copyright

    Affiliations: Herbal Medicine Resources Group, Korea Institute of Oriental Medicine, Daejeon 305‑811, Republic of Korea
  • Pages: 499-502
    |
    Published online on: October 17, 2014
       https://doi.org/10.3892/mmr.2014.2698
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Cancer metastases are not always cured by chemotherapy. Conventional and alternative drugs, including Chinese herbal remedies, have been developed to target metastatic cancer cells. Smilax china L. (SCL), a member of the Smilacaceae family, exerts anti‑inflammatory, detoxification and anti‑cancer effects. However, the effect of SCL on breast cancer cell metastasis and the underlying mechanisms are yet to be elucidated. The aim of this study was to investigate the effect of a SCL ethanol extract (SCLE) on the proliferation and migration of MDA‑MB‑231 human breast cancer cells, as well as the expression of urokinase plasminogen activator (uPA), uPA receptor (uPAR) and tissue inhibitors of metalloproteinases (TIMPs). Cell proliferation was assessed using the Cell Counting Kit‑8 and cell migration was determined by wound healing assay. Quantitative polymerase chain reaction was performed to quantify the mRNA levels of uPA, uPAR and TIMPs. SCLE markedly inhibited the proliferation and migration of MDA‑MB‑231 cells, and reduced the mRNA levels of the extracellular matrix (ECM) degradation‑associated molecules uPA, uPAR. By contrast, SCLE significantly increased the mRNA levels of TIMP1 and TIMP2. These findings show that SCLE exerts an anti‑metastatic effect on human breast cancer cells, which may involve the modulation of ECM degradation.

Introduction

Breast cancer is the second leading cause of cancer-related mortality among females worldwide. Although improved screening techniques have aided the detection of breast cancer at the early stages and advanced treatments have markedly improved patient survival, tumor invasion and metastasis still contribute to the majority of breast cancer-associated mortalities (1).

Metastasis is a series of events that involves the detachment of tumor cells from the primary tumor site, their adhesion, migration and invasion into blood or lymphatic vessels and their interaction with target tissues. The invasion of tumor cells into target tissues results in the formation of secondary tumors (2,3). These events occur repeatedly during tumor invasion, and perturbation of the adhesiveness and motility of tumor cells and their invasion into target tissues has been proposed as a method of preventing cancer progression (4,5).

Plants are valuable sources of natural therapeutic compounds. Research into oriental medicines has increased over the past decade, with the aim of identifying novel drugs, including anti-cancer agents (6–8). Several herb-based constituents and extracts have been found to reduce tumor growth and inhibit the metastasis of human cancer cells in in vitro and in vivo models (9,10). Therefore, such compounds may be valuable tools in cancer therapy.

Smilax china L. (SCL), a member of the Smilacaceae family, is used in Traditional Chinese Medicine as a diuretic and detoxification agent and to treat various conditions, including rheumatic arthritis, lumbago, gout, tumors and inflammatory diseases (11). Pharmacological investigations indicate that SCL exhibits anti-tumor (12) and anti-inflammatory (13) effects. However, the effect of SCL ethanol extract (SCLE) treatment on the highly metastatic MDA-MB-231 human breast cancer cell line is yet to be elucidated. Therefore, in the present study, the anti-metastatic effect of SCLE on MDA-MB-231 cells was investigated.

Materials and methods

Materials

All plastic materials were purchased from Falcon Labware (Becton Dickinson and Company, Franklin Lakes, NJ, USA). Fetal bovine serum (FBS), phosphate-buffered saline and penicillin G/streptomycin were obtained from Gibco-BRL (Grand Island, NY, USA). RPMI-1640 medium was purchased from Welgene, Inc. (Daegu, Korea). The Cell Counting Kit-8 (CCK-8) was obtained from Dojindo Molecular Technologies, Inc. (Gaithersburg, MD, USA).

Preparation of plant extracts

SCL was purchased as a dried herb from Omniherb Co. (Yeoungcheon, Korea). The dried bark of SCL (200 g) was extracted twice using 70% ethanol with 2 h reflux, and the extract was concentrated under reduced pressure. The decoction was filtered, lyophilized and stored at 4°C. The yield of dried extract from the starting crude material was ~12.7% (w/w). The SCLE was diluted in culture media to the final concentrations indicated for each experiment.

Cell culture

MDA-MB-231 cells were obtained from the American Type Culture Collection (Rockville, MD, USA) and cultured in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin. The culture was performed at 37°C in 5% CO2. Subsequent to reaching 80% confluence, the cells were detached using 0.25% trypsin-EDTA. Cells were then subcultured further.

Cell viability assay

Water-soluble tetrazolium salt-8, which is reduced to yellow water-soluble formazan by the dehydrogenase released from mitochondria, was the effective constituent of the CCK-8. Absorbance was measured at 450 nm using a Benchmark Plus Microplate Spectrophotometer (Bio-Rad, Hercules, CA, USA). Cytotoxicity was expressed as a percentage of the absorbance measured in the control and SCLE-treated cells.

Wound healing assay

MDA-MB-231 cells were plated in a 12-well plate at a concentration of 5×105 cells/well and allowed to form a confluent monolayer for 24 h. Cells were wounded using a yellow pipette tip and cellular debris was removed by washing with RPMI-1640 medium. The wounded monolayer was incubated in the presence or absence of SCLE (25 and 50 μg/ml) for 24 h in either RPMI-1640 plus 10% FBS as a positive control or RPMI-1640 plus 1% FBS (CON). Images were captured of the cell migration into the wounded area using phase-contrast microscopy.

Quantitative polymerase chain reaction (qPCR)

qPCR was performed using the Rotor-Gene 3000 (Corbett Research, Sydney, Australia) system using SYBR® Green Master Mix (Qiagen, Tokyo, Japan). The percentage of target gene expression relative to the control was normalized using the GAPDH internal control according to the 2−ΔΔCt analysis. Primers for the target genes were designed using Primer3 software (Table I) (14).

Table I

Primer sequences used in quantitative polymerase chain reaction analysis.

Table I

Primer sequences used in quantitative polymerase chain reaction analysis.

GenesForwardReverseAccession numberLength (bp)
uPA ACCCAAAGAAGGAGGACTAC GTGTAGGATGAGGTTTTCCANM_002658101
uPAR GGTTGTGTGTGGGTTAGACT CTCTCACAGCTCATGTCTGANM_002659117
TIMP1 TGGACTCTTGCACATCACTA GATGGATAAACAGGGAAACANM_003254133
TIMP2 GCTCTGTTGATTTTGTTTCC CTGCTTGTCAACTTTCAACANM_003255125
GAPDH TCAAGCTCATTTCCTGGTAT GTGAGGGTCTCTCTCTTCCTNM_002046141

[i] uPA, urokinase plasminogen activator; uPAR, uPA receptor; TIMP, tissue inhibitor of metalloproteinase.

Statistical analysis

Statistical analyses were performed using the Prism 5 software (GraphPad Software, Inc., San Diego, CA, USA). Analysis of variance followed by a Dunett’s test were performed. A value of P<0.05 was considered to indicate a statistically significant difference.

Results

Effect of SCLE on MDA-MB-231 cell viability

The cytotoxic effect of SCLE was investigated in three cancer cell lines (HepG2, A549 and MDA-MB-231) using the CCK-8. SCLE was observed to reduce the viability of each of these cell lines in a concentration-dependent manner (Fig. 1A). However, SCLE was found to have a weaker effect on the viability of A549 and MDA-MB-231 cells than that of HepG2 cells. SCLE was observed to reduce the viability of MDA-MB-231 cells from 100 to 60% in a concentration- and time-dependent manner (Fig. 1B). The viability of MDA-MB-231 cells was significantly reduced following treatment with 100–400 μg/ml SCLE for 12 or 24 h (P<0.01) (Fig. 1B). Based on these results, non-cytotoxic concentrations of SCLE (25 and 50 μg/ml) were used in further experiments.

Figure 1

SCLE treatment reduces MDA-MB-231 cell viability. (A) HepG2, A549 and MDA-MB-21 cells were treated with various concentrations of SCLE for 24 h. (B) MDA-MB-231 cells were treated with various concentrations of SCLE for 9, 12 and 24 h. Cell viability was then estimated using the Cell Counting Kit-8. Data are presented as the mean ± standard deviation of triplicate samples. **P<0.01 and ***P<0.001 vs. untreated cells. SCLE, Smilax china L ethanol extract.

Effect of SCLE on the metastatic potential of MDA-MB-231 cells

Due to the highly invasive nature of triple-negative breast cancers, the present study investigated the effect of SCLE on the invasive potential of MDA-MB-231 cells in vitro. A wound healing assay was performed to determine the effect of SCLE on the inhibition of MDA-MB-231 cell migration. Twenty-four hours after cell monolayers were wounded, control cell monolayers (RPMI-1640 plus 1% FBS) had completely filled the wounded area. SCLE treatment was observed to inhibit the migration of MDA-MB-231 cells in a concentration-dependent manner (Fig. 2A). Densitometric analysis showed that treatment with 50 μg/ml SCLE reduced the migration of MDA-MB-231 cells by ~50% (Fig. 2B). These results suggest that SCLE effectively inhibits the migration of the highly invasive MDA-MB-231 breast cancer cell line.

Figure 2

SCLE treatment reduces MDA-MB-231 cell migration. MDA-MB-231 cells were treated with 25 or 50 μg/ml SCLE for 24 h. Alternatively, cells were treated with 10% FBS as a positive control or with 1% FBS (CON). (A) Cell migration into the wounded area (indicated by dashed lines) was observed using an inverted phase contrast microscope (magnification, ×200). (B) Quantitative assessment of the number of cells in the wounded area is expressed as the mean ± standard deviation of three independent experiments. **P<0.01 and ***P<0.001 vs. CON cells. SCLE, Smilax china L ethanol extract; FBS, fetal bovine serum.

Effect of SCLE on the expression of extracellular matrix (ECM) degradation-associated molecules

The overexpression and activation of urokinase plasminogen activator (uPA) and the uPA receptor (uPAR) play an important role in the invasion of breast cancer cells by stimulating ECM degradation and thereby promoting cell migration. Therefore, the present study aimed to investigate whether the SCLE-induced inhibition of migration in MDA-MB-231 cells correlated with modulation of uPA and uPAR. SCLE treatment was found to reduce the mRNA levels of uPA and uPAR in a concentration-dependent manner (Fig. 3). By contrast, the mRNA levels of tissue inhibitor of metalloproteinase (TIMP) 1 and 2 were significantly increased following SLCE treatment (P<0.05). These data suggest that the SCLE-mediated inhibition of MDA-MB-231 cell migration and metastasis may be dependent on the degradation of the ECM.

Figure 3

SCLE treatment alters the mRNA levels of extracellular matrix degradation-associated molecules in MDA-MB-231 cells. (A and B) Cells were treated with various concentrations of SCLE for 24 h. uPA, uPAR TIMP1 and TIMP2 mRNA levels were determined using quantitative polymerase chain reaction. Data are expressed as the mean ± standard deviation of triplicate samples. *P<0.05 and **P<0.01 vs. untreated cells. uPA, urokinase plasminogen activator; uPAR, uPA receptor; TIMP, tissue inhibitor of metalloproteinase; SCLE, Smilax china L ethanol extract.

Discussion

In patients with cancer, mortality is rarely a direct consequence of the growth of the primary tumor, but of primary tumor metastasis. Therefore, the prevention and suppression of tumor invasion and metastasis may be a promising strategy for improving the survival of patients with malignant tumors. The present study aimed to investigate the anti-metastatic effects of SCLE, a Chinese herbal medicine, and the mechanisms underlying these effects. SCLE was found to have an anti-metastatic effect on human breast cancer cells. SCLE reduced MDA-MB-21 cell migration in a concentration-dependent manner in vitro (Fig. 2), indicating that SCLE has potent anti-metastatic activity in vitro.

Metastasis is the major cause of mortality in patients with cancer, and is a multifaceted process that results from coordinated events, including cancer cell invasion, migration and adhesion (15). Proteolytic enzyme-induced degradation of the ECM and basement membrane and the subsequent invasion of cancerous cells are essential early steps in metastasis (16). uPA is an important proteolytic enzyme that degrades the ECM, and the expression of uPA and uPAR is associated with increased tumor cell invasion and metastasis in breast cancer (17,18). It is well established that overexpression of uPA in breast cancer is a strong indicator of poor prognosis. uPA binds uPAR on the cell membrane and subsequently degrades cell surface-associated plasminogen (19). Therefore, the present study investigated whether the anti-invasive effect of SCLE in MDA-MB-21 cells correlated with the inhibition of uPA and uPAR activity. SCLE treatment was observed to reduce the mRNA levels of uPA and uPAR (Fig. 3A). Matrix metalloproteinases are a large group of proteolytic enzymes that are involved in degrading and remodeling the ECM in response to a number of pathological stimuli (20). These enzymes are controlled by their endogenous inhibitors TIMP1 and TIMP2 (21). Therefore, increased TIMP activity can inhibit cancer cell invasion and metastasis (22,23). SCLE treatment increased the mRNA levels of TIMP1 and TIMP2 in MDA-MB-231 cells (Fig. 3B). These effects correlated with the inhibition of MDA-MB-231 cell invasion by SCLE.

The present study has demonstrated that SCLE effectively suppresses invasiveness in the MDA-MB-231 human breast cancer cell line. The mechanism underlying this effect may involve modulation of uPA, uPAR and TIMP expression. The results of this study indicate that SCLE may be a potential agent for the treatment of cancer metastasis.

Acknowledgements

This study was supported by the Construction of the Basis for Practical Application of Herbal Resources (no. K12020) from the Korea Institute of Oriental Medicine.

References

1 

Kundu N, Campbell P, Hampton B, Lin CY, Ma X, Ambulos N, Zhao XF, Goloubeva O, Holt D and Fulton AM: Antimetastatic activity isolated from Colocasia esculenta (taro). Anti-cancer Drugs. 23:200–211. 2012. View Article : Google Scholar

2 

Song G, Ohashi T, Sakamoto N and Sato M: Adhesive force of human hepatoma HepG2 cells to endothelial cells and expression of E-selectin. Mol Cell Biomech. 3:61–68. 2006.PubMed/NCBI

3 

Weber GF: Molecular mechanisms of metastasis. Cancer Lett. 270:181–190. 2008. View Article : Google Scholar

4 

Festuccia C, Bologna M, Gravina GL, Guerra F, Angelucci A, Villanova I, Millimaggi D and Teti A: Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components. Int J Cancer. 81:395–403. 1999. View Article : Google Scholar

5 

Festuccia C, Guerra F, D’Ascenzo S, Giunciuglio D, Albini A and Bologna M: In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int J Cancer. 75:418–431. 1998. View Article : Google Scholar : PubMed/NCBI

6 

Hu H, Ahn NS, Yang X, Lee YS and Kang KS: Ganoderma lucidum extract induces cell cycle arrest and apoptosis in MCF-7 human breast cancer cell. Int J Cancer. 102:250–253. 2002. View Article : Google Scholar

7 

Lee SM, Li ML, Tse YC, et al: Paeoniae Radix, a Chinese herbal extract, inhibit hepatoma cells growth by inducing apoptosis in a p53 independent pathway. Life Sci. 71:2267–2277. 2002. View Article : Google Scholar : PubMed/NCBI

8 

Cheng YL, Lee SC, Lin SZ, Chang WL, Chen YL, Tsai NM, Liu YC, Tzao C, Yu DS and Harn HJ: Anti-proliferative activity of Bupleurum scrozonerifolium in A549 human lung cancer cells in vitro and in vivo. Cancer Lett. 222:183–193. 2005.PubMed/NCBI

9 

Wang XF, Du J, Zhang TL, Zhou QM, Lu YY, Zhang H and Su SB: Inhibitory effects of PC-SPESII herbal extract on human breast cancer metastasis. Evid Based Complement Alternat Med. 2013:8943862013.PubMed/NCBI

10 

Shimizu T, Torres MP, Chakraborty S, Souchek JJ, Rachagani S, Kaur S, Macha M, Ganti AK, Hauke RJ and Batra SK: Holy Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: potential role in therapy. Cancer Lett. 336:270–280. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Health Department and National Chinese Medicine Management Office. State Administration of Traditional Chinese Medicine of People’s Republic of China. Zhong-hua-ben-cao, Shanghai Science and Technology Publisher; Shanghai, China: pp. 157–160. 1999

12 

Li YL, Gan GP, Zhang HZ, Wu HZ, Li CL, Huang YP, Liu YW and Liu JW: A flavonoid glycoside isolated from Smilax china L. rhizome in vitro anticancer effects on human cancer cell lines. J Ethnopharmacol. 113:115–124. 2007.

13 

Shu XS, Gao ZH and Yang XL: Anti-inflammatory and anti-nociceptive activities of Smilax china L. aqueous extract. J Ethnopharmacol. 103:327–332. 2006. View Article : Google Scholar

14 

Koressaar T and Remm M: Enhancements and modifications of primer design program Primer3. Bioinformatics. 23:1289–1291. 2007. View Article : Google Scholar : PubMed/NCBI

15 

Kim MS, You MK, Rhuy DY, Kim YJ, Baek HY and Kim HA: Loquat (Eriobotrya japonica) extracts suppress the adhesion, migration and invasion of human breast cancer cell line. Nutr Res Pract. 3:259–264. 2009.

16 

Bogenrieder T and Herlyn M: Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 22:6524–6536. 2003. View Article : Google Scholar : PubMed/NCBI

17 

Du J, Wang XF, Zhou QM, Zhang TL, Lu YY, Zhang H and Su SB: Evodiamine induces apoptosis and inhibits metastasis in MDA-MB-231 human breast cancer cells in vitro and in vivo. Oncol Rep. 30:685–694. 2013.PubMed/NCBI

18 

Andres SA, Edwards AB and Wittliff JL: Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance. J Clin Lab Anal. 26:93–103. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Dan K, Behrendt N, Brunner N, Ellis V, Ploug M and Pyke C: The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis. 8(Suppl 1): 189–203. 1994. View Article : Google Scholar

20 

Brinckerhoff CE and Matrisian LM: Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 3:207–214. 2002. View Article : Google Scholar : PubMed/NCBI

21 

Figueira RC, Gomes LR, Neto JS, Silva FC, Silva ID and Sogayar MC: Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer. 9:202009. View Article : Google Scholar

22 

Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res. 51(18 Suppl): 5054s–5059s. 1991.PubMed/NCBI

23 

Albini A, Melchiori A, Santi L, Liotta LA, Brown PD and Stetler-Stevenson WG: Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst. 83:775–779. 1991. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Nho KJ, Chun JM and Kim HK: Anti‑metastatic effect of Smilax china L. extract on MDA‑MB‑231 cells. Mol Med Rep 11: 499-502, 2015.
APA
Nho, K.J., Chun, J.M., & Kim, H.K. (2015). Anti‑metastatic effect of Smilax china L. extract on MDA‑MB‑231 cells. Molecular Medicine Reports, 11, 499-502. https://doi.org/10.3892/mmr.2014.2698
MLA
Nho, K. J., Chun, J. M., Kim, H. K."Anti‑metastatic effect of Smilax china L. extract on MDA‑MB‑231 cells". Molecular Medicine Reports 11.1 (2015): 499-502.
Chicago
Nho, K. J., Chun, J. M., Kim, H. K."Anti‑metastatic effect of Smilax china L. extract on MDA‑MB‑231 cells". Molecular Medicine Reports 11, no. 1 (2015): 499-502. https://doi.org/10.3892/mmr.2014.2698
Copy and paste a formatted citation
x
Spandidos Publications style
Nho KJ, Chun JM and Kim HK: Anti‑metastatic effect of Smilax china L. extract on MDA‑MB‑231 cells. Mol Med Rep 11: 499-502, 2015.
APA
Nho, K.J., Chun, J.M., & Kim, H.K. (2015). Anti‑metastatic effect of Smilax china L. extract on MDA‑MB‑231 cells. Molecular Medicine Reports, 11, 499-502. https://doi.org/10.3892/mmr.2014.2698
MLA
Nho, K. J., Chun, J. M., Kim, H. K."Anti‑metastatic effect of Smilax china L. extract on MDA‑MB‑231 cells". Molecular Medicine Reports 11.1 (2015): 499-502.
Chicago
Nho, K. J., Chun, J. M., Kim, H. K."Anti‑metastatic effect of Smilax china L. extract on MDA‑MB‑231 cells". Molecular Medicine Reports 11, no. 1 (2015): 499-502. https://doi.org/10.3892/mmr.2014.2698
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team